Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.57 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.48 |
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.48 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.48 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.48 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.48 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.48 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.46 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.46 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474403 | 0.98 | SIGMAR1 (0.59) | SIGMAR1SLC18A3HTR2CP2RY14QDPR | |
| SCHEMBL31386222 | 0.87 | JAK3 (0.59) | JAK3 | |
| Hydrochloric Acid SCHEMBL4290507 | 0.86 | TSHR (0.55) | DRD1 | |
| Hydrochloric Acid SCHEMBL7394020 | 0.84 | PARP1 (0.46) | SIGMAR1SLC18A3HTR2CP2RY14HTR1A | |
| SCHEMBL901209 | 0.84 | TSHR (0.57) | DRD1 | |
| SCHEMBL2321634 | 0.84 | TSHR (0.57) | DRD1 | |
| SCHEMBL901207 | 0.84 | TSHR (0.57) | DRD1 | |
| Hydrochloric Acid SCHEMBL3630728 | 0.84 | CYP2C9 (0.54) | SIGMAR1SLC18A3HTR2CQDPRESRRB | |
| Hydrochloric Acid SCHEMBL4005490 | 0.84 | HTR2C (0.50) | SIGMAR1SLC18A3HTR2CP2RY14QDPR | |
| SCHEMBL18553793 | 0.82 | SLC18A3 (0.63) | SIGMAR1SLC18A3HTR2CP2RY14QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-4232437-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | Liangjiang Medicine Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| EP-3184520-B1 | SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF | EISAI R&D MAN CO LTD (JP) | 2022-03-23 | — | — | EP | disclosed |
| CN-110372703-A | Five-ring heterocycles miazines compound and application thereof | 罗欣生物科技（上海）有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-9951047-B2 | Salt of monocyclic pyridine derivative and crystal thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170217935-A1 | SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3184520-A1 | SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2017-06-28 | — | — | EP | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| CN-104520290-A | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH INC | 2015-04-15 | — | — | CN | disclosed |
| US-8933099-B2 | Monocyclic pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| EP-1902044-A1 | 5-HTX MODULATORS | Bio Medisinsk Innovasjon AS (NO) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007072-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2007-01-18 | — | — | WO | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| EP-0604800-A1 | 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-07-06 | — | — | EP | disclosed |
| EP-0592949-A2 | N-(aminocarbonyl)-piperidines/pepirazines as aggregation inhibiting agents | Dr. Karl Thomae GmbH (DE) | 1994-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217935-A1 | SALT OF MONOCYCLIC PYRIDINE DERIVATIVE AND CRYSTAL THEREOF | MPST, SLC25A1, SLC16A1 | SIGMAR1 2820/4885HTR2C 4139/4885HTR1A 4250/4885 |
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | SIGMAR1 555/4885HTR2C 2611/4885HTR1A 2186/4885 |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | FGFR2, FGFR1, FGFR3 | SIGMAR1 398/4885HTR2C 331/4885HTR1A 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.